MoonLake Immunotherapeutics

MLTX Healthcare Biotechnology

In the quarter to June 2026, EPS grew 3.45%, free cash flow fell 1.89% and total debt rose 35.6%, each against the same quarter a year earlier.

9.55 0.71 −6.92%
Market cap
$873.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
12.56 8.60 9.27 8.50

+8 more quarters

Net Debt/EBITDA
7.20 3.74 4.96 4.34
Debt/Equity
0.23 0.39 0.24 0.25
Free Cash Flow per Share
(0.75) (0.93) (0.91) (0.70)
Book value per Share
5.79 3.56 4.72 4.60
Free Cash Flow
(55.56) (66.29) (58.79) (44.54)
Other line items

Show all line items

Columns are period end dates